{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T21:10:14Z","timestamp":1793653814458,"version":"4.5.1"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2022,6,30]],"date-time":"2022-06-30T00:00:00Z","timestamp":1656547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,6,30]],"date-time":"2022-06-30T00:00:00Z","timestamp":1656547200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1007\/s13555-022-00752-8","type":"journal-article","created":{"date-parts":[[2022,6,30]],"date-time":"2022-06-30T13:07:47Z","timestamp":1656594467000},"page":"1623-1637","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Meaningful Changes in What Matters to Individuals with Vitiligo: Content Validity and Meaningful Change Thresholds of the Vitiligo Area Scoring Index (VASI)"],"prefix":"10.1007","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5519-0794","authenticated-orcid":false,"given":"Helen","family":"Kitchen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen W.","family":"Wyrwich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chloe","family":"Carmichael","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda S.","family":"Deal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatjana","family":"Lukic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamara","family":"Al-Zubeidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Marshall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Pegram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iltefat H.","family":"Hamzavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brett","family":"King","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,6,30]]},"reference":[{"issue":"9988","key":"752_CR1","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/S0140-6736(14)60763-7","volume":"386","author":"K Ezzedine","year":"2015","unstructured":"Ezzedine K, Eleftheriadou V, Whitton M, van Geel N. Vitiligo. Lancet. 2015;386(9988):74\u201384.","journal-title":"Lancet"},{"issue":"6","key":"752_CR2","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1111\/jdv.12171","volume":"28","author":"R Speeckaert","year":"2014","unstructured":"Speeckaert R, van Geel N. Distribution patterns in generalized vitiligo. J Eur Acad Dermatol Venereol. 2014;28(6):755\u201362.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"6","key":"752_CR3","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1001\/archderm.140.6.677","volume":"140","author":"I Hamzavi","year":"2004","unstructured":"Hamzavi I, Jain H, McLean D, Shapiro J, Zeng H, Lui H. Parametric modeling of narrowband UV-B phototherapy for vitiligo using a novel quantitative tool: the Vitiligo Area Scoring Index. Arch Dermatol. 2004;140(6):677\u201383.","journal-title":"Arch Dermatol"},{"issue":"10244","key":"752_CR4","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/S0140-6736(20)30609-7","volume":"396","author":"D Rosmarin","year":"2020","unstructured":"Rosmarin D, Pandya AG, Lebwohl M, Grimes P, Hamzavi I, Gottlieb AB, et\u00a0al. Ruxolitinib cream for treatment of vitiligo: a randomised, controlled, phase 2 trial. Lancet. 2020;396(10244):110\u201320.","journal-title":"Lancet"},{"issue":"2","key":"752_CR5","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1111\/bjd.13432","volume":"172","author":"L Komen","year":"2015","unstructured":"Komen L, Da Gra\u00e7a V, Wolkerstorfer A, De Rie M, Terwee C, van der Veen J. Vitiligo Area Scoring Index and Vitiligo European Task Force assessment: reliable and responsive instruments to measure the degree of depigmentation in vitiligo. Br J Dermatol. 2015;172(2):437\u201343.","journal-title":"Br J Dermatol"},{"key":"752_CR6","doi-asserted-by":"crossref","unstructured":"Bae JM, Zubair R, Ju HJ, Kohli I, Lee HN, Eun SH, et\u00a0al. Development and validation of the fingertip unit for Assessing Facial Vitiligo Area Scoring Index (F-VASI). J Am Acad Dermatol. 2021.","DOI":"10.1016\/j.jaad.2021.06.880"},{"key":"752_CR7","unstructured":"US Food and Drug Administration. Guidance for industry patient-reported outcome measures: use in medical product development to support labeling claims. 2009. https:\/\/www.fda.gov\/media\/77832\/download. Accessed 18 Aug 2021."},{"key":"752_CR8","unstructured":"US Food and Drug Administration. Patient-focused drug development: collecting comprehensive and representative input. 2020. https:\/\/www.fda.gov\/media\/139088\/download. Accessed 18 Aug 2021."},{"issue":"1","key":"752_CR9","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.jval.2016.11.005","volume":"20","author":"JH Powers III","year":"2017","unstructured":"Powers JH III, Patrick DL, Walton MK, Marquis P, Cano S, Hobart J, et\u00a0al. Clinician-reported outcome assessments of treatment benefit: report of the ISPOR clinical outcome assessment emerging good practices task force. Value Health. 2017;20(1):2\u201314.","journal-title":"Value Health"},{"issue":"6","key":"752_CR10","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/j.jval.2015.08.006","volume":"18","author":"MK Walton","year":"2015","unstructured":"Walton MK, Powers JH III, Hobart J, Patrick D, Marquis P, Vamvakas S, et\u00a0al. Clinical outcome assessments: conceptual foundation\u2014report of the ISPOR clinical outcomes assessment\u2013emerging good practices for outcomes research task force. Value Health. 2015;18(6):741\u201352.","journal-title":"Value Health"},{"key":"752_CR11","unstructured":"U.S. Food and Drug Administration. Public meeting on patient-focused drug development for Vitiligo: transcript. 2021. https:\/\/www.fda.gov\/media\/146995\/download. Accessed 22 Oct 2021."},{"issue":"1","key":"752_CR12","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1111\/pcmr.12561","volume":"30","author":"EY Gan","year":"2017","unstructured":"Gan EY, Eleftheriadou V, Esmat S, Hamzavi I, Passeron T, B\u00f6hm M, et\u00a0al. Repigmentation in vitiligo: position paper of the Vitiligo Global Issues Consensus Conference. Pigment Cell Melanoma Res. 2017;30(1):28\u201340.","journal-title":"Pigment Cell Melanoma Res"},{"issue":"3","key":"752_CR13","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1111\/bjd.17013","volume":"180","author":"V Eleftheriadou","year":"2019","unstructured":"Eleftheriadou V, Hamzavi I, Pandya A, Grimes P, Harris J, Huggins R, et\u00a0al. International Initiative for Outcomes (INFO) for vitiligo: workshops with patients with vitiligo on repigmentation. Br J Dermatol. 2019;180(3):574\u20139.","journal-title":"Br J Dermatol"},{"issue":"1","key":"752_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s41687-019-0100-y","volume":"3","author":"H Staunton","year":"2019","unstructured":"Staunton H, Willgoss T, Nelsen L, Burbridge C, Sully K, Rofail D, et\u00a0al. An overview of using qualitative techniques to explore and define estimates of clinically important change on clinical outcome assessments. J Patient Rep Outcomes. 2019;3(1):1\u201310.","journal-title":"J Patient Rep Outcomes"},{"key":"752_CR15","doi-asserted-by":"crossref","unstructured":"Kitchen HGK, Johnson C, Wyrwich KW, Lukic T, Al-Zubeidi T, Marshall C, Pegram H, King S, King B. A qualitative study to explore the content validity of the Vitiligo Patient Priority Outcome (ViPPO) measures. In: Vitiligo international symposium 2021. 2021.","DOI":"10.1007\/s13555-022-00772-4"},{"key":"752_CR16","unstructured":"US Food and Drug Administration. Patient-focused drug development: methods to identify what is important to patients (draft guidance). 2019. https:\/\/www.fda.gov\/media\/131230\/download. Accessed 18 Aug 2021."},{"issue":"8","key":"752_CR17","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1016\/j.jval.2011.06.014","volume":"14","author":"DL Patrick","year":"2011","unstructured":"Patrick DL, Burke LB, Gwaltney CJ, Leidy NK, Martin ML, Molsen E, et\u00a0al. Content validity\u2014establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO good research practices task force report: part 1\u2014eliciting concepts for a new PRO instrument. Value Health. 2011;14(8):967\u201377.","journal-title":"Value Health"},{"issue":"7","key":"752_CR18","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/j.jval.2017.11.014","volume":"21","author":"DM Turner-Bowker","year":"2018","unstructured":"Turner-Bowker DM, Lamoureux RE, Stokes J, Litcher-Kelly L, Galipeau N, Yaworsky A, et\u00a0al. Informing a priori sample size estimation in qualitative concept elicitation interview studies for clinical outcome assessment instrument development. Value Health. 2018;21(7):839\u201342.","journal-title":"Value Health"},{"issue":"8","key":"752_CR19","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1016\/j.jval.2011.06.013","volume":"14","author":"DL Patrick","year":"2011","unstructured":"Patrick DL, Burke LB, Gwaltney CJ, Leidy NK, Martin ML, Molsen E, et\u00a0al. Content validity\u2014establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO Good Research Practices Task Force report: part 2\u2014assessing respondent understanding. Value Health. 2011;14(8):978\u201388.","journal-title":"Value Health"},{"issue":"5","key":"752_CR20","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1016\/j.jaad.2019.02.008","volume":"81","author":"K Ezzedine","year":"2019","unstructured":"Ezzedine K, Ahmed M, Tovar-Garza A, Hajj C, Whitton M, Pandya A, et\u00a0al. Cross-cultural validation of a short-form of the Vitiligo Impact Patient scale (VIPs). J Am Acad Dermatol. 2019;81(5):1107\u201314.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"752_CR21","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/j.jaad.2015.07.039","volume":"73","author":"K Ezzedine","year":"2015","unstructured":"Ezzedine K, Sheth V, Rodrigues M, Eleftheriadou V, Harris JE, Hamzavi IH, et\u00a0al. Vitiligo is not a cosmetic disease. J Am Acad Dermatol. 2015;73(5):883\u20135.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"752_CR22","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.ijwd.2017.11.005","volume":"4","author":"PE Grimes","year":"2018","unstructured":"Grimes PE, Miller MM. Vitiligo: patient stories, self-esteem, and the psychological burden of disease. Int J Women\u2019s Dermatol. 2018;4(1):32\u20137.","journal-title":"Int J Women's Dermatol"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-022-00752-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-022-00752-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-022-00752-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,10]],"date-time":"2023-02-10T02:56:30Z","timestamp":1675997790000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-022-00752-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,30]]},"references-count":22,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["752"],"URL":"https:\/\/doi.org\/10.1007\/s13555-022-00752-8","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,30]]},"assertion":[{"value":"6 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}